m
Recent Posts
Connect with:
Friday / August 19.
HomeminewsEarly AMD Study Call for Patients

Early AMD Study Call for Patients

Encouraging results from a pilot study conducted at the Centre of Eye Research Australia (CERA) have led to the world’s first multi-centred, randomised controlled trial of nanosecond laser intervention study in early Age-related Macular Degeneration (AMD).[/vc_column_text][/vc_column]

The study is an investigator-initiated study and is being conducted in collaboration with Ellex R&D Pty Ltd, the Australian manufacturer of laser systems for eye diseases. The trial has sites overseas and in Sydney, Perth and Melbourne, with a new site in Adelaide planned soon. Participants attend seven visits over 36 months and receive laser treatment every six months. Fifty per cent of participants will be treated with the laser and the other fifty per cent treated with sham laser.

To be involved in the study participants need to have bilateral intermediate drusen (>125µm) with or without pigmentary changes and best corrected visual acuity of 6/12 or better.

Exclusion criteria are any retinal sign suggestive of geographic atrophy (GA) or choroidal neovascularisation (CNV); sub-foveal pigment epithelial detachment greater than 1000µm in diameter in either eye; and ocular disease in either eye, other than AMD, which may significantly compromise assessment of the retina.

For further information contact Kate Brassington: kbra@unimelb.edu.au or call 03 9929 8360

For further information contact Kate Brassington: kbra@unimelb.edu.au or call 03 9929 8360

You can read more about the trial in an article written for mivision May issue by Professor Robyn Guymer.

DECLARATION

DISCLAIMER : THIS WEBSITE IS INTENDED FOR USE BY HEALTHCARE PROFESSIONALS ONLY.
By agreeing & continuing, you are declaring that you are a registered Healthcare professional with an appropriate registration. In order to view some areas of this website you will need to register and login.
If you are not a Healthcare professional do not continue.